Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to ...

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Avista Therapeutics expands AI gene therapy platform to break barriers in the delivery of genetic medicines: Pittsburgh Monday, January 12, 2026, 16:00 Hrs [IST] Avista Therapeuti ...

Nanoscope has received a new patent ( US Patent No. 12459977) from the US Patent and Trademark Office (USPTO) for the company ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

We’ve turned the calendar on 2026, and the market’s focus is on what comes next. The big questions haven’t changed: can the ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...

Kashiv BioSciences, LLC ("Kashiv"), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of ...